NCT04119830 2022-02-08Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerRoswell Park Cancer InstitutePhase 2 Withdrawn
NCT02615574 2017-09-26A Study of Type-1 Polarized Dendritic Cell (αDC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-α2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal CancerUniversity of PittsburghPhase 2 Withdrawn